The manufacturer of Xamiol® has written to healthcare professionals advising that this product is being discontinued. The same letter advised that the 120g tube size of Dovonex® ointment is being replaced by a 30g tube size.
Xamiol contains calcipotriol and betamethasone in a gel formulation. It was licensed for use in scalp psoriasis. The manufacturer points out that Dovobet Gel is an identical product with a wider license; it can be used on the body as well as the scalp.
Dovonex ointment (calcipotriol) is also being replaced by a 30g tube size which the manufacturer says will allow greater flexibility to prescribe clinically appropriate quantities for smaller areas of psoriasis.
Action: Clinicians should be aware of these changes. Current prescriptions for Xamiol can be changed to generic to allow continued supply and quantities of Dovonex prescribed can be amended if necessary at routine reviews.
|« Reappraisal of Metformin||Drug Safety Update - April 2012 »|